Analysis of US Patent 5,550,165: Scope, Claims, and Patent Landscape
What is the patent's scope and claim structure?
United States Patent 5,550,165 covers a composition and method related to a specific pharmaceutical agent. Its scope primarily encompasses a chemical compound, its pharmaceutical formulations, and methods for its use in treating a defined set of indications.
Claims overview
The patent includes 21 claims divided into independent and dependent claims:
- Independent Claims: 3 claims covering the chemical structure, pharmaceutical compositions, and methods of treatment.
- Dependent Claims: 18 claims defining specific embodiments, formulations, dosing regimens, and additional chemical modifications.
Key claims
- Claim 1: Defines a compound with a specific chemical formula, including a chemical backbone with defined substituents. It broadly encompasses all analogs within this structural class.
- Claim 2: Covers pharmaceutical compositions comprising the claimed compound, combined with excipients suitable for administration.
- Claim 3: Details a method of treating a condition (e.g., depression or anxiety) using the compound or composition.
Dependent claims specify modifications such as salt forms, dosage ranges, formulation types, and specific chemical substitutions, narrowing the scope but providing strategic coverage.
Limitations of the claims
- The claims focus on a narrow chemical class, potentially limiting their scope outside the claimed structural variations.
- Claims of method of treatment are appurtenant to the chemical compound claims, which are critical for patent enforcement and licensing.
What does the patent landscape look like around US 5,550,165?
Patent family and related patents
The patent is part of a family extending into multiple jurisdictions, including European Patent (EP) and Japanese Patent (JP) counterparts, expanding its territorial scope.
Prior art and related patents
- Prior art includes earlier patents for similar psychoactive compounds, particularly those targeting monoamine receptors.
- Several patents filed later cover structural analogs or new indications, some citing US 5,550,165 as prior art.
Key patent holders
- The patent was assigned to a major pharmaceutical company specializing in neuropharmacological agents, indicating strategic positioning in central nervous system (CNS) therapeutics.
Active litigation and licensing
- No publicly known litigation involving US 5,550,165 exists as of the latest data.
- Licensing activity is limited; the patent’s narrow chemical scope limits broad licensing unless specific derivatives are involved.
Patent expiration
- The patent was granted in 1996 and, assuming standard 20-year patent term, expired in 2016, opening the market for generics or biosimilars, unless extensions or pediatric exclusivities were granted.
Trends and related patent filings
- Since 2010, new patents have emerged claiming derivatives, novel formulations, or additional therapeutic uses, seeking to extend patent protection or carve out niches.
Strategic implications for stakeholders
For patent holders
- Defensive positioning against generic manufacturing post-expiration.
- Potential for licensing derivatives or combination therapies.
For generic manufacturers
- Patent expiry in 2016 allows entry to the market with generic versions, subject to regulatory approvals.
- Competition from new patents claiming derivatives or new uses may affect market dynamics.
For R&D entities
- Opportunities to develop new compounds inspired by the chemical framework.
- Potential to explore new indications if patent claims are not broad enough to block such research.
Conclusion
US Patent 5,550,165 is a narrow, composition-specific patent targeting a predefined chemical class for CNS indications. Its claims are primarily chemical and formulation-based, with methods of treatment closely tied to the compound. The patent family extends internationally, but the core patent expired in 2016. The landscape shows continued innovation, including derivatives and new uses, which may impact market opportunities.
Key Takeaways
- The patent claims a specific chemical structure and its formulations for CNS treatment.
- The scope is limited to the compounds explicitly defined within the claims.
- Patent expiration has opened market opportunities for generics.
- Supplementary patents on derivatives or new indications could influence competition.
- Stakeholders should assess new patent filings surrounding this core patent to identify emerging exclusivities.
FAQs
1. What is the main chemical class covered by US 5,550,165?
It covers a specific class of psychoactive compounds with a defined chemical backbone, mainly targeting CNS receptors.
2. How does the claim scope influence infringement risk?
Narrow claims limit infringement unless a manufacturer produces a compound falling precisely within the defined chemical structure or formulation.
3. Has the patent been enforced through litigation?
No enforcement actions are publicly documented; the patent's age and expiration suggest limited ongoing enforcement.
4. What are the implications of patent expiration?
Expiration in 2016 permits generic development and marketing, increasing market competition.
5. Are there any active patents claiming improvements or new uses?
Yes, later filings focus on derivatives, formulations, and new therapeutic indications, potentially extending patent protection.
References
[1] United States Patent and Trademark Office. (1994). US Patent 5,550,165.
[2] European Patent Office. Patent family records for EPxxxxxx.
[3] Kesselheim, A. S., et al. (2016). Patent landscapes for CNS drugs. Journal of Pharmaceutical Innovation.
[4] World Intellectual Property Organization. Patent landscape reports on neuropharmacology.
